Hanall Biopharma (009420)

Currency in KRW
53,800
-200(-0.37%)
Closed·
009420 is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
52,60055,000
52 wk Range
35,10073,000
Key Statistics
Bid/Ask
53,100.00 / 53,300.00
Prev. Close
53,800
Open
53,400
Day's Range
52,600-55,000
52 wk Range
35,100-73,000
Volume
239.69K
Average Volume (3m)
260.88K
1-Year Change
22.4118%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
009420 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
90,000
Upside
+67.29%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Pharmaceuticals industry

Hanall Biopharma News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 90,000
(+67.29% Upside)

Earnings

Latest Release
Nov 13, 2026
EPS / Forecast
60.00 / 54.40
Revenue / Forecast
39.91B / --
EPS Revisions
Last 90 days

009420 Income Statement

Compare 009420 to Peers and Sector

Metrics to compare
009420
Peers
Sector
Relationship
P/E Ratio
−123.6x2.8x−0.2x
PEG Ratio
0.120.000.00
Price/Book
17.8x0.5x2.6x
Price / LTM Sales
16.9x0.5x2.6x
Upside (Analyst Target)
67.3%31.0%76.9%
Fair Value Upside
Unlock35.3%14.9%Unlock

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson’s disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves’ disease; and HL187 and HL186 for immuno-oncology. The company was founded in 1973 and is headquartered in Daejeon, South Korea.

Employees
287

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.07M4.07%108.19B
Other Institutional Investors
27.22M53.52%1.42T
Public Companies & Retail Investors
21.57M42.41%1.13T
Total
50.86M100.00%2.66T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Daewoong Pharmaceutical Co., Ltd31.69%16,115,745842,853,464
The National Pension Fund10.92%5,552,260290,383,198

People Also Watch

209,500
018260
-2.33%
449,500
128940
+6.52%
45,500
030200
-3.81%
39,200
112610
-5.43%
27,600
004020
-3.16%

FAQ

What Is the Hanall Biopharma (009420) Stock Price Today?

The Hanall Biopharma stock price today is 53,800 KRW.

What Stock Exchange Does Hanall Biopharma Trade On?

Hanall Biopharma is listed and trades on the Seoul Stock Exchange.

What Is the Stock Symbol for Hanall Biopharma?

The stock symbol for Hanall Biopharma is "009420."

What Is the Hanall Biopharma Market Cap?

As of today, Hanall Biopharma market cap is 2.74T KRW.

What Is Hanall Biopharma's Earnings Per Share (TTM)?

The Hanall Biopharma EPS (TTM) is -426.76.

When Is the Next Hanall Biopharma Earnings Date?

Hanall Biopharma will release its next earnings report on Jan 20, 2027.

From a Technical Analysis Perspective, Is 009420 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Hanall Biopharma Stock Split?

Hanall Biopharma has split 3 times.

How Many Employees Does Hanall Biopharma Have?

Hanall Biopharma has 287 employees.

What is the current trading status of Hanall Biopharma (009420)?

As of Nov 21, 2026, Hanall Biopharma (009420) is trading at a price of 53,800 KRW, with a previous close of 53,800 KRW. The stock has fluctuated within a day range of 52,600 KRW to 55,000 KRW, while its 52-week range spans from 35,100 KRW to 73,000 KRW.

What Is Hanall Biopharma (009420) Price Target According to Analysts?

The average 12-month price target for Hanall Biopharma is 90,000 KRW, with a high estimate of 110000 KRW and a low estimate of 68000 KRW. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +67.29% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.